Related Experiment Videos
Preliminary clinical experience with the Bard XT coronary stent
D Pentousis1, Y Guérin, X Favereau
1Department of Interventional Cardiology, Centre Médico-Chirurgical Parly-Grand Chesnay, Le Chesnay, France.
American Heart Journal
|November 13, 1998
Summary
The Bard XT stent, a novel coronary stent, demonstrated high success rates in delivery and treatment. Preliminary findings suggest its safety and efficacy for coronary lesions.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Biomedical Engineering
Background:
- The Bard XT stent features a novel design with discrete zigzag modules on a flexible longitudinal spine.
- This balloon-expandable stent represents a new approach to coronary artery treatment.
Purpose of the Study:
- To evaluate the safety and efficacy of the newly introduced Bard XT coronary stent.
- To assess the performance of this innovative stent in a patient cohort.
Main Methods:
- A study involving 81 patients (107 lesions) who received 108 Bard XT stents.
- The study included 66% elective procedures, assessing stent delivery and angiographic outcomes.
Main Results:
- Achieved 97.1% primary success in stent delivery and 100% angiographic success.
- Significantly improved minimal luminal diameter from 0.79 mm to 2.55 mm, reducing stenosis from 76% to 9%.
- Observed two cases of subacute thrombosis at 1 and 3 days post-procedure; no other major complications noted.
Conclusions:
- The Bard XT stent shows a promising design for safe and effective treatment of coronary lesions.
- Its efficacy extends to patients with high-risk clinical and unfavorable angiographic characteristics.